NeuBase Therapeutics, Inc. NBSE

Full chart Compare
Set alert

Price alert · NBSE

All alert types
0.38 0.00 (+0.00%)

At closeMay 10, 2024, 4:00 PM EDT

0.365 Day range 0.3914

52-week range unavailable

Market cap
1.42M
Shares out
3.75M
Forward P/E
-0.03
Volume
89.70K
Open
0.381
Previous close
0.378
Day's range
0.365 – 0.3914
Beta
0.94
Analysts
Hold
Earnings date
Dec 26, 2024

2Y -18.9320 (-98.04%)

0.000010.000020.0000Aug 22Dec 22May 23Oct 23Mar 240.3780

Key statistics

Enterprise value
-5.83M
PEG ratio
0.00
Price / sales
0.00
Price / book
0.15
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-15.18M
Total cash
12.57M
Total debt
5.34M
Return on equity
-93.46%
Short % of float
0.44%
50-day average
0.472587
200-day average
0.722122

Financials — quick view

All financials
NBSE Revenue — quarterly 0
2020-Q1 20192020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20202021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20212022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 2023
NBSE Net income — quarterly -1.82M
2020-Q1 20192020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20202021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20212022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 2023
NBSE EPS — quarterly -0.66
2020-Q1 20192020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20202021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20212022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20222023-Q2 20232023-Q3 20232023-Q4 2023

Earnings

NBSE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 26, 2024Sep 1, 20240.00———
Sep 30, 2024Jun 1, 20240.00———
Jul 4, 2024Mar 1, 20240.00———
Nov 9, 2023Sep 1, 2023-1.82-0.95+0.87+47.80%
Aug 14, 2023Jun 1, 2023-1.80-1.26+0.54+30.00%

About NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on NBSE — it syncs with the Stock Master app.

Insider holders

NBSE insider holders
InsiderRelationLatest transactionDateShares held
ALMENOFF JUNE SHERIEDirectorPurchaseFeb 5, 201516,900
BACKENROTH SAMUELChief Financial OfficerPurchaseApr 29, 202011,630
BRANNING TODD PChief Financial OfficerStock Award(Grant)Mar 15, 202384,200
GOLDSTEIN DOV ADirectorPurchaseJun 17, 202130,000
HIRSCHMAN ORINDirectorPurchaseApr 9, 20170
MANN WILLIAM ROLANDChief Operating OfficerPurchaseMar 29, 202211,200

Institution ownership

NBSE institution ownership
Holder% heldSharesValueReported
Armistice Capital, LLC7.03%166,174310.75KJun 29, 2023
Greenlight Capital, Inc.5.77%136,350254.97KJun 29, 2023
Point72 Asset Management, L.P.2.65%62,500116.88KJun 29, 2023
Decheng Capital Management III (Cayman), LLC2.12%50,00093.50KJun 29, 2023
Carnegie Mellon University1.99%46,97087.83KJun 29, 2023
Kestra Advisory Services, LLC1.08%25,48347.65KJun 29, 2023

Fund ownership

NBSE fund ownership
Holder% heldSharesValueReported
Vanguard Extended Market Index Fund0.80%18,98135.49KJun 29, 2023
Jacob Discovery Fd0.66%15,65515.19KAug 30, 2023
Fidelity Extended Market Index Fund0.30%7,08125.22KMay 30, 2023
Fidelity Series Total Market Index Fund0.06%1,4255.08KMay 30, 2023
Fidelity Total Market Index Fund0.06%1,3594.84KMay 30, 2023
Schwab Capital Trust-Total Stock Market Index Fund0.06%1,4852.06KJul 30, 2023